We report the results of a pilot study of a BU-fludarabinealemtuzumab (BFA)-reduced toxicity conditioning (RTC) followed by allogeneic hematopoietic SCT (AlloHSCT) in 12 children and adolescents (o21 years) with malignant and non-malignant diseases. Stem cell sources were: two unrelated cord blood, one unrelated BM, two related and seven unrelated PBSC. Positive CD34 selection was performed in five unrelated PBSC grafts. RCT was carried out with BFA, and GVHD prophylaxis was FK506 and mycophenolate mofetil. The median time for neutrophil and platelet engraftment was 16 and 31 days, respectively. The P of developing Xgrade II, Xgrade III aGVHD and cGVHD was 41.6, 25 and 9%, respectively. Only 1 out of 12 developed Xgrade III toxicity. There was one primary and no secondary graft failure. Mixed donor chimerism on day 100 and 1 year was median 99 and 96%, respectively; X90% of recipients achieved X80% donor chimerism. The 3-year overall survival (OS) in all patients was 91.7 ± 8% (100% for malignant vs 80% for non-malignant diseases, ns). In all, 11 (91%) patients remain alive at median 2.8 (0.3-6.8) years. RTC followed by AlloHSCT, based on BFA conditioning, is feasible and tolerable in children and adolescents, and results in prompt achievement of durable mixed donor chimerism and excellent OS.
Introduction
Reduced toxicity conditioning (RTC) followed by hematopoietic SCT (HSCT) has improved the accessibility of transplantation in patients previously ineligible. [1] [2] [3] RTC is defined as a regimen associated with myeloablation but associated with reduced toxicity secondary to conditioning. We and others have demonstrated RTC HSCT regimens to be safe and efficacious in a wide range of hematologic malignancies. [2] [3] [4] [5] [6] [7] RTC regimens also offer an alternative that reduces regimen-related toxicity and morbidity in adult patients with significant co-morbidities. 2, 3, 6, 8 One of the most often used RTC regimens is based on BU and fludarabine. The development of i.v. BU and its incorporation in the preparative regimens for AlloHSCT has changed transplantation, initially for myelogenous malignancies; the use of i.v. BU-based conditioning is extending rapidly also to HSCT for lymphoid malignancies, genetic diseases and umbilical cord blood transplantation (UCBT). 1 RTC HSCT in children may be associated with reduction in TRM and long-term late complications, as well as length of hospitalization, use of blood products, and risk of infections. [3] [4] [5] 7 In the malignant setting, RTC HSCT eradicates malignant cells through a graft vs malignancy effect provided by alloreactive donor T-lymphocytes and/ or natural killer cells. In patients with non-malignant diseases RTC HSCT provides enough immunosuppression to promote engraftment and correct underlying genetic defects. [3] [4] [5] 7 The introduction of BU, fludarabine and rabbit antithymocyte globulin (ATG) conditioning in children receiving a transplant from a mismatched unrelated donor resulted in excellent overall survival (OS), and provided sustained engraftment in patients undergoing transplant from matched sibling and unrelated donors, though it did not provide sustained engraftment in the majority of children with non-malignancies undergoing mismatched unrelated donor transplants.
As a more intensified immunosuppression seemed to be an appropriate approach in RTC with BU and fludarabine, ATG was replaced by alemtuzumab in adult studies. Results of allografting following conditioning with BU, fludarabine and alemtuzumab (BFA) in adult patients with AML or myelodysplastic syndrome from matched sibling donors or volunteer unrelated donors showed that RTC AlloHSCT using this protocol appeared to be safe and permitted durable donor engraftment. 8, 10 It was also found that delayed attainment of full donor chimerism after alemtuzumab-based RTC HSCT for AML and myelodysplastic syndrome was associated with improved outcomes. 8 Unfortunately, there are no safety or efficacy data for using BFA RTC in pediatric AlloHSCT. We report our experience of RTC HSCT using conditioning with BFA in 12 children and adolescent recipients with malignant and non-malignant diseases, who received hematopoietic stem cells from either sibling or unrelated donors. In our study, not only was ATG changed to alemtuzumab, but also 2-day BU was changed to 4-day BU when compared with the traditional reduced intensity conditioning BU/ fludarabine/ATG. Besides determining the safety of this RTC regimen, we hypothesized that this RTC regimen would result in sustained mixed donor chimerism. We wanted to see sustained mixed donor chimerism with a variety of patients with a heterogeneous stem cell source.
Materials and methods

Patients
Between July 2002 and December 2008, RTC with BFA AlloHSCT was performed using both related and unrelated donors in 12 recipients that were o21 years of age with malignant (n ¼ 7) and non-malignant diseases (n ¼ 5) (Table 1) . Patients with sickle cell disease are excluded in this analysis and will be reported in a separate manuscript. Patients were eligible if they had a fully matched or a one or two Ag mismatched family donor, an unrelated adult donor or unrelated CB unit with a minimum cryopreserved cell dose of X2 Â 10 7 total nucleated cells per kg. All patients required a 450% Lansky (p16 years) or Karnofsky (416 years) performance status before study entry. Research protocols were either disease specific or cell donor specific. Patients or families were offered a choice between myeloablation, RCT or reduced intensity conditioning (2 day BU). The decision was determined between the patient and the treating physicians. All patients or parents signed informed consents and assents were signed when applicable. All protocols, informed consents and assents were approved by the Institutional Review Board of Columbia University Medical Center. All research protocols were in compliance with the Declaration of Helsinki Principle.
HLA typing and match HLA-A, HLA-B and HLA-C Ag typing was performed by intermediate resolution molecular testing, and HLA-DRB1 and HLA-DQB1 allele typing was determined by hybridization of PCR-amplified DNA with sequence-specific oligonucleotide probes, as we previously described.
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Confirmatory typing was performed at Columbia University Medical Center. The criteria for graft matching included at least 4-5/6 loci for UCBT or 8 out of 10 or greater for peripheral blood/BM.
Conditioning regimen
The conditioning regimen consisted of i.v. BU from day À8 to À5, total of 16 mg/kg p4 years and 12.8 mg/kg for 44 years, 4 days, total 8 doses. The fludarabine dose was 30 mg per m 2 per day given from day À8 to À3 (total dose 180 mg/ m 2 ), and alemtuzumab (Campath-1H) dose was 2 mg per m 2 per day (max 3 mg) on day À6, 6 mg per m 2 per day (max 10 mg) on day À5 and À4, 20 mg per m 2 per day (max 30 mg) on day À3 and À2 (total dose 54 mg/m 2 , max 83 mg). Before alemtuzumab administration, premedication was given with: acetaminophen 10 mg/kg (max 650 mg) orally (p.o.), diphenhydramine 1 mg/kg (max 50 mg) and methylprednisolone 1 mg/kg (max 50 mg). All patients received phenytoin (8-10 mg per kg per day) or keppra (levetiracetam, 5-10 mg per kg per day) as seizure prophylaxis with BU administration.
BU pharmacokinetic (PK)
Blood samples for BU PK analysis were collected in heparinized tubes 60 min into the first infusion, at the end of the first infusion, and 1, 3, 4, 5 and 6 h after completion of the first infusion. All PK analyses were performed using gas chromatography-mass spectrometry at the University of Pennsylvania. 12 Patients with steady-state concentration (Css) or area under the plasma concentration-time curve (AUC) outside of the target ranges of 600-900 ng/mL or 1800-2400 mmol min/L, respectively, were subject to dose adjustment generally by the fifth dose for twice daily dosing of BU. The new dose was calculated assuming linear proportionality of dose and Css or AUC using the formula: Dose (new)-Dose [1] Â AUC (desired) /AUC [1] . After each dose adjustment, repeat analysis of PK parameters was performed. Repeat analyses required sample collection immediately before the infusion, at the end of infusion, and 4, 5 and 6 h after completion of the infusion. AUC and Css estimates for individual subjects were determined by fitting the measuredblood BU concentrations for each subject to a one-compartment, first order kinetic model using the WinNonLin Version 3.1 Software package (Pharsight Inc, Cary, NC, USA).
AlloHSCT (related donors and unrelated CB donors)
Recipients of HLA-matched and mismatched family donors received filgrastim-stimulated PB using standard apheresis procedures or filgrastim-stimulated allogeneic BM using standard BM harvesting procedures following a dose of filgrastim (10 mg per kg per day) for 4 days with collection by either apheresis or BM harvest on the fifth day for a minimum target dose of 5.0 Â 10 6 CD34 þ cells/kg recipient body wt. Recipients of progenitor cells from unrelated CB donors with a pre-thaw dose of X2.0 Â 10 7 nucleated cells/kg received thawed unrelated CB progenitor cells as we and others have described. [13] [14] [15] CD 34 selection and quantitation in matched unrelated donors In patients with non-malignant disorders receiving an unrelated PBSC, a positive CD34 þ selection was the priority in this subgroup. The selection of progenitors from donor leukapheresis products was done with the Isolex (Nexell Therapeutics, Irvine, CA, USA) cell selection system with anti-CD34-coated magnetic microbeads. 16 Graft characteristics are shown in Table 2 . CD34 quantitation was performed by the ProCount method by flow cytometry (Becton Dickinson, San Jose, CA, USA). The percent CD34/45 was multiplied by the automated WBC to obtain the total CD34 in the product. The final postmanipulation WBC was used to enumerate the absolute no. of CD34 þ cells as well as the total no. of CD3 þ cells, which was also enumerated by flow cytometry. 14 Tacrolimus was started either on first day of conditioning regimen or day À1 and MMF began on day þ 1. MMF was not given to patients who received CD34 selected matched unrelated donor grafts. MMF was stopped if patients had pgrade II aGVHD on day þ 30 for malignant diseases and day þ 180 for non-malignant diseases. 17 Tacrolimus was tapered over 8 weeks starting on day þ 60 in patient with malignant disease and day þ 180 in patient with non-malignant disease. AGVHD and cGVHD were graded according to Seattle criteria. 18 All patients who achieved any level of donor chimerism were considered at risk for developing aGVHD. Only patients with sustained engraftment of donor hematopoiesis and surviving for more than 100 days after transplant were evaluated for the development of cGVHD. 
Supportive care
All patients were hospitalized in protective isolation defined as private or single rooms with HEPA filtration system and reverse isolation, requiring mask and strict hand washing. Isolation, antibacterial, antifungal and antiviral prophylaxis were performed according to institutional protocols. Broad-spectrum antibiotics were used to treat initial episodes of febrile neutropenia. All patients received sargramostim (250 mg per m 2 per day) i.v. once daily from day 0 until the WBC reached X300/mm 3 Â 2 days, and then were switched to filgrastim (10 mg per kg per day) either i.v. or subcutaneously until an ANC of X2500/mm 3 was achieved for 3 days as we described previously. 19 Herpes simplex prophylaxis consisted of acyclovir (250 mg/m 2 ) i.v. three times a day from day þ 5 until engraftment and pgrade II mucositis. Pneumocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole until day À2 and then resumed three times weekly after myeloid engraftment. Patients unable to tolerate trimethoprim/sulfamethoxazole received i.v. pentamidine prophylaxis every 2 weeks. Fungal prophylaxis consisted of liposomal amphotericin B (3 mg per kg per day) i.v. starting on day 0 through day þ 100 as we described previously. 20 Patients who were CMV sero positive and/or received an AlloHSCT from a CMV sero-positive donor were given prophylactic foscarnet (90 mg per kg per day i.v. every other day) alternating with ganciclovir (5 mg per kg per dose i.v. every other day) starting after myeloid engraftment until day þ 100 if there was no GVHD, as we previously described 21 and those with documented CMV infection were treated with ganciclovir and i.v. IgG.
Irradiated, leukodepleted, packed red blood cell transfusions of 10-15 cc/kg were given to maintain Hgb X 8.0 g/ dL. Irradiated leukodepleted platelet transfusions of 1 unit/ 10 kg body wt were administered to maintain platelet counts above 10 Â 10 9 /L. All blood products were leukodepleted using a p250-micron filter and irradiated with 2500 cGy. All CMV sero-negative patients with CMV sero-negative donors received leukocyte reduced or CMV sero-negative blood products to prevent transfusionassociated CMV infection.
Engraftment and chimerism
Neutrophil recovery was defined as an ANC of 500/mm 3 for 3 consecutive days. Platelet recovery was defined as a platelet count of 20 000/mm 3 independent of platelet transfusions for at least 7 days. Primary myeloid graft failure was defined as failure to achieve a donor-derived ANC X500/mm 3 by day þ 42 and p50% whole-blood donor chimerism by day þ 60. Donor chimerism was measured on days þ 30, 60, 100, 180 and 365 and yearly after transplant.
Chimerism was determined in whole blood using a PCR-based method involving amplification of genes containing STRs, as we have previously described. 22 For each donor-recipient pair, informative alleles were determined for STR loci (selected from D16S539, D3S1358, FGA, D7S820, D2S1338, D10S2325, D12S391, SE33, CSFR, VWF, D21S11, D11S1294, D18S51, D16S486, D4S243, AMGY/AMGXA, HUMFIBRA, PENTA D and PENTA E).
If multiple loci were informative, two loci were selected for post-transplant testing for each donor-recipient pair. Full donor chimerism was defined when X99% cells were of donor origin, and mixed chimerism in case of o99% donor cells.
Immune reconstitution
Lymphocyte subpopulations T, B and natural killer cells were analyzed in whole blood with flow cytometry using MoAb: anti-CD3, anti-CD19, anti-CD56 (Beckman Coulter, or BD Biosciences, San Jose, CA, USA). The absolute no.s of the different subpopulations analyzed were calculated from the total no. of PBLs, the proportion of forward scatter/side scatter lymphocyte region gate and the percentage of positive cells within the gate. 23 IgA, IgM and IgG serum levels were assessed by ELISA method. The analyses were carried out on: day þ 100, þ 180 and þ 360 after transplant. 
Statistics
Probabilities of neutrophil recovery, platelet recovery, aGVHD, cGVHD, regimen-related death (non-relapse mortality) and survival were estimated using the KaplanMeier method and statistical significance was calculated using the log-rank method. 24 Poor-risk patients were defined as patients with malignant disease with refractory/ relapsed disease and/or CR 3 or beyond. Additionally, patients undergoing a second AlloSCT were considered poor risk. The remaining patients were classified as average risk. Relapse was defined by morphological and/or radiological evidence of malignant disease in any site and was considered as time interval between UCBT and relapse, with censoring at death or CR. TRM was defined as all causes of non-relapse death before 100 days after transplant. OS was the time between transplantation and death because of any cause or between transplantation and the day of last follow-up. The median survival of this patient group was estimated with a 95% confidence interval. Kaplan-Meier curves were used to summarize survival. Cumulative incidence functions were used to summarize time to engraftment and time to GVHD.
Results
Demographics
From July 2002 to December 2008, 12 patients with malignant and non-malignant diseases received RTC with BFA. Characteristics of the patients are summarized in Table 1 . The median age was 16 years (range, 2-20 years) and the median follow-up was 2.8 years (range, 0.3-6.8). There were six males and six females. Seven patients were transplanted for malignant disease: CML (chronic phase, n ¼ 4), acute promyelocytic leukemia (CR2, n ¼ 1), nonHodgkin lymphoma (CR3, n ¼ 1), human T-lymphotrophic virus-1 adult T-cell leukemia lymphoma (PD, n ¼ 1). Five patients were transplanted for non-malignant diseases, all with stable disease: severe aplastic anemia (n ¼ 3), scleroderma (n ¼ 1), Wolman 0 s Disease (n ¼ 1). Patients received AlloHSCTs from either related PBSC (n ¼ 2), unrelated PBSC (n ¼ 7), unrelated UCB (n ¼ 2) or unrelated BM (n ¼ 1). Donor sources and degree of mismatch are listed in Table 2 . Positive CD34 selection was done in five unrelated PBSCT. Patients were classified as either average risk (n ¼ 10) or poor risk (n ¼ 2) on the basis of their pre-transplant history and disease status (Tables 1 and 2 ). One patient with anaplastic large cell lymphoma had previously had a primary graft failure after a UCBT and subsequently relapsed and was reinduced into a CR3.
For recipients of unselected related or unrelated BM/ PBSC, the mean total nucleated cell dose/kg was 77.7 Â 10 7 and the mean CD34 cell dose/kg was 4.51 Â 10 6 . Mean total nucleated cell and CD34 counts for recipients of unrelated UCB were 3.3 Â 10 7 and 2.8 Â 10 5 cells/kg, respectively. For recipients of unrelated CD34-selected PBSC, the mean total nucleated cell dose/kg was 0.7 Â 10 7 , the mean CD34 cell dose/kg was 5.03 Â 10 6 and the mean CD3 cell dose was 1.9 Â 10 5 .
Hematologic recovery
In all, 11 patients were evaluable for myeloid recovery (ANC X500/mm 3 Â 3 days). One patient died before myeloid engraftment. The median time to myeloid engraftment for all evaluable patients was 16 days (16 days vs 16 days for unselected PBSC/BM/CB vs selected PBSC recipients, NS) (Figure 1a) . In three patients platelet count did not drop below 20 000/mm 3 . Seven patients were evaluable for platelet engraftment (untransfused platelet count X20 000/mm 3 Â 7 days). The median time to platelet engraftment was 31 days (27 days vs 35 days for unselected PBSC/BM/CB vs selected PBSC recipients, ns) (Figure 1b) .
Maximal chimerism following transplantation was 100% Â 7, 99% Â 2, 94% Â 1, 80% Â 1 and 48% Â 1. One primary graft failure occurred secondary to CMV disease in a 10-year old female with scleroderma.
Incidence and severity of acute and chronic GVHD Five patients developed grade II-IV aGVHD with a median of 29 days (range, 18-41). The P of developing grade II-IV aGVHD or grade III-IV aGVHD was 41.6 and 25%, respectively (Figure 2a) . cGVHD was evaluated in children surviving more than 100 days. In all, 1 out of 11 patients developed cGVHD with limited gut disease. The KaplanMeier estimate of cGVHD P was 9% (Figure 2b) .
Among five patients after CD34 selection, two developed aGVHD (one skin stage II, and one skin stage III and gut stage III), none of them developed cGVHD. Among seven patients, who received transplant without CD34 selection, three developed aGVHD (one skin stage II, and two gut stage III), one of them developed limited gut cGVHD.
Donor chimerism
Donor chimerism was evaluated in 12 patients at day 30, in 9 patients at day 60 and 8 patients at day 100. By day 30, patients had reached 93.2 ± 9.7%, by day 60, 88.6 ± 17.4% and by day 100, 96.6 ± 5.7% donor chimerism (Figure 3a) . Median whole-blood donor chimerism on days 30, 60, 100, 180 and 365 was 99.5% (48-100), 99% (10-99), 98.5% (82-100), 98% (66-99) and 96% (55-99), respectively.
Grade III to grade IV non-hematological toxicities
Only one patient developed grade IV non-hematological, noninfectious toxicity. This patient with Wolman's syndrome developed transient elevation of liver transaminases (ALT 1630 IU/L, AST 2171 IU/L) on day þ 2, followed by hyperbilirubinemia (max total bilirubin 53.1 mg/dL at day þ 18). This patient required a cadaveric liver transplant for acute hepatic failure and is now no evidence of disease.
Infectious complications
All patients had triple-lumen broviac catheters placed before the transplant. All blood cultures were drawn from the central venous line only. As PB cultures were not performed, some of the bloodstream isolates reported may represent contaminants, rather than actual pathogens. All lumens of the central venous line were cultured if a patient developed a fever (X100.41F).
In all, 6 of 12 patients (50%) developed central venous line bacteremia, with 5 patients having polymicrobial infections. In total, 13 incidents of grade III and grade IV bacteremia/sepsis were observed during the study period: coagulase negative staphylococcus sp (n ¼ 4), Staphylococcus aureus (n ¼ 2), gram-negative bacteria (n ¼ 4) and other gram-positive bacteria (n ¼ 3). In each incident the patients fully recovered with appropriate antimicrobial therapy.
Three patients developed invasive fungal infections (Aspergillus sp) (n ¼ 1) (post-mortem) and Candida glabrata lung infection (n ¼ 1) (day þ 27), fungemia with Candida krusei (n ¼ 1) (day ¼ 191). All patients with Candida infection resolved their infection with appropriate antibiotic therapy.
Three patients developed hematuria of viral etiology: polyoma BK (n ¼ 2) (days þ 81 and þ 10) and adenovirus (n ¼ 1) (day þ 16). Patients were treated with 5 mg/kg of cidofovir once a week with good outcome. Other infections included disseminated adenovirus (n ¼ 2), CMV pneumonitis (n ¼ 1), RSV (n ¼ 1), parainfluenza (n ¼ 1), mycobacteria (n ¼ 1) and HSV mucositis (n ¼ 1), treated successfully with antiviral agents.
One patient received a CD34 selected unrelated adult donor developed an EBV negative lymphoproliferative diagnosis approximately 10 months after transplant. This patient received a donor lymphocyte infusion and developed liver GVHD which resolved upon treatment and is now no evidence of disease.
Disease-free survival
Two patients with CML developed minimal molecular disease and were treated with donor lymphocyte infusions and are no evidence of disease. One patient with CML developed persistent cytogentic relapse.
Survival
The 3-year OS for all patients was 91.7±8% ( Figure 3b) . P of 3-year OS for patients with malignant diseases was 100% and for patients with non-malignant diseases 80% (P ¼ NS).
A total of 11 patients remain alive at median 2.8 (0.3-6.8) years. One patient died of invasive Aspergillus infection at day þ 40 (developed hyperacute GVHD which was treated with steroids, tacrolimus and MMF). This patient had full donor chimerism in peripheral blood, but failed to achieve full reconstitution of the neutrophil count. Thus, the incidence of TRM was 1 out of 12 (9%).
BU PKs
In all, 10 of 12 subjects (83%) underwent PK analysis ( Table 3) . The mean AUC, Css, and confidence interval were 2141.6 ± 206.7 mmol min/L, 732.7 ± 70.7 ng/mL, and 3.34 ± 0.38 mL per min per kg, respectively. Two patients had a Css below 600 ng/mL after the first BU dose, whereas one had a Css above 900 ng/mL. All three patients with initial Css values outside of the target range were dose adjusted.
Immune reconstitution Full T-cell reconstitution (CD34200/mL) and B-cell reconstitution (CD194200/mL) was delayed until 1 year after HSCT (Table 4 ). The recovery of natural killer cells (CD56 þ ) occurred as early as day þ 100 and remained normal thereafter. Time to recovery of lymphocyte populations, and time to recovery of Igs was similar in patients after CD34 þ selection vs others.
Discussion
In children, myeloablative AlloHSCT is not only associated with acute short-term toxicities but also long-term late complications such as growth retardation, infertility and secondary malignancies. Despite the success of RTC AlloHSCT in adults, more studies are still necessary in child and adolescent recipients to define the appropriate patient population, optimal conditioning regimens, cost benefits, survival and differences in short-term and longterm effects compared with conventional myeloablative conditioning. 7 In this study, we present our experience with a BFA RTC AlloHSCT in 12 children and adolescents (o21 years) with malignant and non-malignant diseases.
The BFA regimen in children and adolescents was well tolerated, provided consistent high donor chimerism despite use of 1 family mismatched and 10 out of 12 unrelated donors (including 2 UCBT and 5 CD34-selected). In total, 9 out of 12 patients (including those with CML diagnosis) were chemonaive, however, high-sustained mixed donor chimerism 490% was obtained, despite the impact of a no. of risk factors. Only one primary and no secondary graft failure was observed.
BFA RTC provided sustained engraftment in most children with malignant and non-malignant diseases undergoing mismatched related or unrelated donor transplants. Receiving a transplant from a mismatched unrelated donor was not identified as a risk factor for graft failure in our study. We have shown that BFA conditioning is feasible and tolerable in children and adolescents, and results in prompt achievement of durable mixed donor chimerism. The regimen was very well tolerated, resulted in excellent OS, with low toxicity and low aGVHD and cGVHD rate in patients undergoing transplant from matched sibling and unrelated donors. There are several possible explanations for these advantages. First, replacement of rabbit ATG by alemtuzumab in the conditioning regimen. This drug could be responsible for the prolonged immunosuppression of the recipient's immune system, thus enabling the development of stable and durable mixed donor chimerism. Another important factor related to alemtuzumab use was delayed immune recovery, especially in the subpopulation of B-lymphocytes, extending far beyond 6 months. This required prolonged supportive therapy however, it did not impair engraftment. Secondly, GVHD prophylaxis was performed with MMF/tacrolimus (FK506) in our patients, whereas CsA and MTX were used in the Horn et al. study. 9 We have previously shown that the use of FK506/MMF has been associated with good tolerability and low overlapping toxicities, and it may be equivalent or superior to standard regimens in preventing aGVHD with the appropriate monitoring. 17, 25 Thirdly, faster implementation of growth factors, which were started at day 0 in our study, whereas day þ 21 in the Horn et al. study. 9 As sequential administration of GM-CSF/G-CSF post-myeloablative AlloHSCT was safe, and resulted in prompt myeloid this can possibly contribute to more sustained engraftment. Fourthly, the dose of BU was twofold higher than in the study by Horn et al., 9 providing stronger immunosuppression.
In our study, BU was administered daily in two divided doses Â 4 days. This regimen has not been previously described in children. Most commonly, BU is given daily in four divided doses. The two doses per day approach in this study can lead to savings related to dosing in time and cost in comparison with four doses per day. BU kinetics studies were available in 10 out of 12 patients. One patient with primary graft failure had a BU steady state concentration of 656 ng/mL. As three patients had lower steady state concentrations, this probably did not contribute to graft failure.
Another issue of the BFA regimen was its highly immunosuppressive nature, increasing the risk of infectious complications. We used liposomal amphotericin B as antifungal prophylaxis in all patients. We have previously shown high efficacy with this approach. 20 However, in 3 out of 12 (25%) patients, invasive fungal infections occurred in this study. This high invasive fungal infection ratio, especially in the early post-transplant period, could contribute to risk of death, as was the case in the patient with hyperacute GVHD who required early administration of steroids that contributed to increased immunosuppression. Prolonged neutropenia and hyperacute GVHD were major risk factors for this patient. Another infectious complication related to use of alemtuzumab could be viral infection; although only one patient suffered from CMV reactivation and CMV-pneumonia, whereas two others had disseminated adenovirus infections, successfully treated with ganciclovir. Thus, because of the high risk of infectious complication, the question arises if the dose of alemtuzumab should be decreased. The use of alemtuzumab leads to an increased risk of infectious complications, due to delayed immune recovery. Despite the risk of infections, the supportive therapy which has been provided in most cases was sufficient. One patient developed post-transplant lymphoproliferative disease, which is a life-threatening complication, occurring especially after transplants from unrelated donors and after T-depletion. [26] [27] [28] The risk of non-infectious, non-hematologic complications was low in our patient cohort. There were no cases of veno-occlusive disease, although all patients received low-molecular-wt heparin as prophylaxis.
Immune reconstitution after BFA conditioning was characterized by relatively fast natural killer cell recovery within 100 days after transplant, whereas CD3 þ cell and CD19 þ cell recovery was delayed beyond the first year, relatively later in comparison with existing data on immune recovery after HSCT in children, especially in those under age of 10 years. 29, 30 It is known that T-and B-cell recovery in peripheral blood occurs later in children receiving alemtuzumab than in those who receive ATG. 31 Also, transplantation of PBSC in children seemed to elicit the fastest reconstitution of CD3
þ CD3 þ and naı¨ve T-cells compared with BM or CD34-selected PBSC, which did not differ. 32, 33 No significant differences in immune recovery between CD34 selected PBSC vs others were observed in our cohort of patients, presumably because the use of alemtuzumab caused immunosuppression in all patients regardless of stem cell source and manipulation. On the other hand, no significant delay in post-transplant Ig subset levels was observed, which suggests relatively good function of B lymphocytes within the first post-transplant year after BFA conditioning, in spite of their decreased absolute peripheral blood count.
Our results suggest that BFA conditioning is an efficacious reduced toxicity regimen for a variety of pediatric and adolescent recipients, which provides good OS and sustained chimerism, although delayed immune recovery and increased risk of infectious complications requires more intensified anti-infectious prophylaxis and supportive therapy. Very close monitoring of CMV and galactommanan and more of a pre-emptive approach may lead to improvement of results. Recently we started the administration of micofungin to replace liposomal amphotericin B. Alemtuzumab is known to be effective in decreasing the incidence of GVHD without increasing the risk of relapse, 31 thus highly contributing to decrease in TRM. With BFA conditioning, survival was consistent or even better when compared with pediatric recipients undergoing myeloablative therapy, even after correction to average risk group patients, which were in the majority of our group.
In summary, we recommend further study of BFA conditioning as a promising allogeneic transplant conditioning regimen. Future study directions should also be related to alemtuzumab PKs and possibly reducing the dose of alemtuzumab in the RTC regimen. Due to prolonged immunosuppression caused by alemtuzumab, careful infection monitoring and prophylaxis need to be integrated in the future.
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